The sodium-glucose cotransporter-2 inhibitor canagliflozin alleviates endothelial dysfunction in a rat bypass model
Ischemia/reperfusion (IR) injury during coronary artery bypass grafting surgery has detrimental impacts on endothelial integrity and function. Studies have suggested that canagliflozin (CANA) mitigates the risk of cardiovascular events, independently of diabetes. We hypothesized that the supplementation and/or administration of CANA protects vascular grafts in a bypass model in non-diabetic Lewis rats. The aortic arches of control rats (n = 9) were harvested, aortic rings were prepared, then mounted in organ baths. In the IR and IR + CANA<sub>suppl</sub> groups (n = 8/group), aortic arches were preserved in either saline or CANA-supplemented saline (5 µM) for 1 h at 4 °C before transplantation. In the IR + CANA<sub>inject</sub> and IR + CANA<sub>suppl+inject</sub> groups (n = 9/group), aortic arches were preserved in cold saline or CANA for 1 h and recipients received CANA (10 µg/kg, intravenous) 5 min prior to reperfusion. After 1 h of in vivo blood reperfusion, ex vivo vascular function was assessed and immunohistochemistry was performed. The decreased maximum relaxation (R<sub>max</sub>) to acetylcholine in the IR group compared to controls (20 ± 3 % vs 83 ± 2 %, p < 0.05) was improved in both the IR + CANA<sub>inject</sub> (36 ± 2 % vs. 20 ± 3 %, p < 0.05) and IR + CANA<sub>suppl+inject</sub> (45 ± 3 % vs. 20 ± 3 %, p < 0.05) groups. Additionally, the IR + CANA<sub>suppl+inject</sub> rings exhibited a further increased R<sub>max</sub> to acetylcholine compared to both the IR + CANA<sub>suppl</sub> (45 ± 3 % vs. 31 ± 2 %, p < 0.05) and IR + CANA<sub>inject</sub> (45 ± 3 % vs. 36 ± 2 %, p < 0.05) groups. Increased DNA strand breaks in the IR group compared to controls were decreased in all CANA groups. The reduced immunoreactivity of CD-31 was ameliorated in the IR + CANA<sub>inject</sub> and IR + CANA<sub>suppl+inject</sub> groups. CANA alleviates endothelial dysfunction induced by IR injury in a rodent model of revascularization.
Authors
- Patricia Kraft
- Sevil Korkmaz‐Icöz (ORCID: https://orcid.org/0000-0003-3613-5807)
- Shuo Lian
- Tobias Mayer (ORCID: https://orcid.org/0000-0002-4935-4710)
- Gábor Szabó (ORCID: https://orcid.org/0000-0001-6038-9968)
- Alex Ali Sayour
- Ming Ma (ORCID: https://orcid.org/0000-0002-4572-3267)
- Matthias Karck
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
Publication Details
- Journal
- Biochemical Pharmacology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1016/j.bcp.2025.117601
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00